<DOC>
	<DOCNO>NCT02736162</DOCNO>
	<brief_summary>The primary objective study assess retention rate perampanel give secondary monotherapy routine clinical care .</brief_summary>
	<brief_title>Study Investigate Dosage , Efficacy , Safety Perampanel Given Monotherapy Patients With Epilepsy</brief_title>
	<detailed_description>This study retrospective study participant receive perampanel primary secondary monotherapy approximately 40 center Europe , Asia , Australia . Primary monotherapy define administration perampanel absence concomitant antiepileptic drug ( AEDs ) . Secondary ( conversion ) monotherapy define conversion perampanel adjunctive therapy monotherapy withdraw concomitant AEDs .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Diagnosis epilepsy Received perampanel primary secondary monotherapy time 1 Jan 2013 15 Oct 2015 Provided write informed consent participant participant 's legally authorize representative sign use medical record per local requirement</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Perampanel</keyword>
	<keyword>E2007</keyword>
	<keyword>Phase 4</keyword>
	<keyword>Fycompa</keyword>
</DOC>